NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Inmed Pharmaceuticals Inc. INM
6 fiscal years on record · USD · FY2024 reported
SEC FILINGS ONLY
Revenue · FY2024
$4.9M
▲ 7.5% vs FY2023
EPS · FY24
$-8.36
Dividend / sh · FY24
—
Payout · FY24
—
ROE · FY24
-72.1%
Net margin · FY24
-165.1%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 4.9M
Revenue, FY2024 · full 6-year series below
Revenue
Net income
The company lost 165 cents on every revenue dollar this year.
Per share
USD -8.36
Diluted EPS, FY2024
EPS
The company pays no cash dividend.
Profitability
-72.1%
Return on equity, FY2024
ROE
Operating margin-165.1%
Net margin-165.1%
Return on assets-59.6%
Each USD of equity lost 72 cents this year.
Returned to shareholders
—
returned in FY2024 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+65.5%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.00B
Shares outstanding, FY2024
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 15.6M
total assets, end of FY2024
Total assetsUSD 15.6M
EquityUSD 13.4M
CashUSD 11.1M
Current ratio6.99×
Equity funds 86% of total assets.
History
6 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2024
2023
2022
2021
2020
2019
Revenue $B
0.0
0.0
0.0
0.0
0.0
·
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
·
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.0
·
Income tax $B
·
0.0
0.0
·
·
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−8.36
−20.14
−3.25
−33.17
−37.96
−1.71
Dividend / sh $
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
ROE %
−72.1
−72.1
−75.1
−226.1
−154.0
−152.1
Shares out B
0.00
0.00
0.00
0.00
0.00
0.01
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
22 of 22
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed